Syndax Pharmaceuticals Inc
SNDX21.300USD
-0.300-1.39%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.85BMarket Cap
LossP/E TTM
More Details of Syndax Pharmaceuticals Inc Company
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Syndax Pharmaceuticals Inc Info
Ticker SymbolSNDX
Company nameSyndax Pharmaceuticals Inc
IPO dateMar 03, 2016
CEOMetzger (Michael A)
Number of employees270
Security typeOrdinary Share
Fiscal year-endMar 03
Address730 Third Avenue
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10017
Phone17814191400
Websitehttps://syndax.com/
Ticker SymbolSNDX
IPO dateMar 03, 2016
CEOMetzger (Michael A)
Company Executives of Syndax Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael A. Metzger
Mr. Michael A. Metzger
Chief Executive Officer, Director
Chief Executive Officer, Director
298.66K
--
Mr. Dennis G. Podlesak
Mr. Dennis G. Podlesak
Independent Chairman of the Board
Independent Chairman of the Board
127.33K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
75.00K
+15.38%
Mr. Steven (Steve) Closter
Mr. Steven (Steve) Closter
Chief Commercial Officer
Chief Commercial Officer
70.90K
--
Mr. Pierre Legault, CPA
Mr. Pierre Legault, CPA
Independent Director
Independent Director
65.00K
-10.96%
Mr. Nicholas A.J. Botwood
Mr. Nicholas A.J. Botwood
Head - Research and Development, Chief Medical Officer
Head - Research and Development, Chief Medical Officer
--
--
Ms. Jennifer A. Jarrett
Ms. Jennifer A. Jarrett
Independent Director
Independent Director
--
--
Dr. Aleksandra Rizo, M.D., Ph.D.
Dr. Aleksandra Rizo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Keith A. Goldan, CPA
Mr. Keith A. Goldan, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Martin H. Huber, M.D.
Dr. Martin H. Huber, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael A. Metzger
Mr. Michael A. Metzger
Chief Executive Officer, Director
Chief Executive Officer, Director
298.66K
--
Mr. Dennis G. Podlesak
Mr. Dennis G. Podlesak
Independent Chairman of the Board
Independent Chairman of the Board
127.33K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
75.00K
+15.38%
Mr. Steven (Steve) Closter
Mr. Steven (Steve) Closter
Chief Commercial Officer
Chief Commercial Officer
70.90K
--
Mr. Pierre Legault, CPA
Mr. Pierre Legault, CPA
Independent Director
Independent Director
65.00K
-10.96%
Mr. Nicholas A.J. Botwood
Mr. Nicholas A.J. Botwood
Head - Research and Development, Chief Medical Officer
Head - Research and Development, Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Kynam Capital Management LP
9.80%
BlackRock Institutional Trust Company, N.A.
7.79%
The Vanguard Group, Inc.
5.89%
Goldman Sachs & Company, Inc.
5.57%
Point72 Asset Management, L.P.
4.90%
Other
66.05%
Shareholders
Shareholders
Proportion
Kynam Capital Management LP
9.80%
BlackRock Institutional Trust Company, N.A.
7.79%
The Vanguard Group, Inc.
5.89%
Goldman Sachs & Company, Inc.
5.57%
Point72 Asset Management, L.P.
4.90%
Other
66.05%
Shareholder Types
Shareholders
Proportion
Hedge Fund
49.33%
Investment Advisor
32.89%
Investment Advisor/Hedge Fund
22.13%
Research Firm
12.66%
Venture Capital
1.95%
Individual Investor
1.30%
Pension Fund
0.76%
Bank and Trust
0.34%
Family Office
0.06%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
456
105.70M
121.61%
-16.72M
2025Q2
453
106.14M
123.25%
-9.50M
2025Q1
465
105.51M
122.65%
-11.55M
2024Q4
466
101.18M
117.63%
-2.44M
2024Q3
454
91.99M
107.96%
-12.90M
2024Q2
424
90.42M
106.49%
-16.61M
2024Q1
417
93.25M
109.83%
-11.76M
2023Q4
407
91.08M
107.54%
+9.06M
2023Q3
394
77.71M
113.61%
-12.98M
2023Q2
385
77.69M
113.93%
-12.13M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Kynam Capital Management LP
8.52M
9.89%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
7.56M
8.77%
+745.47K
+10.94%
Jun 30, 2025
The Vanguard Group, Inc.
5.01M
5.82%
+158.25K
+3.26%
Jun 30, 2025
Goldman Sachs & Company, Inc.
5.20M
6.03%
+1.74M
+50.14%
Jun 30, 2025
Point72 Asset Management, L.P.
2.13M
2.47%
-1.88M
-46.93%
Jun 30, 2025
State Street Investment Management (US)
3.44M
4%
-528.98K
-13.32%
Jun 30, 2025
BofA Global Research (US)
3.84M
4.46%
+967.87K
+33.71%
Jun 30, 2025
Eversept Partners, LP
4.07M
4.72%
-146.91K
-3.49%
Jun 30, 2025
Kingdon Capital Management, L.L.C.
2.10M
2.44%
+100.00K
+5.00%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Tema Oncology ETF
2.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
State Street SPDR S&P Biotech ETF
0.47%
Simplify Health Care ETF
0.33%
Direxion Daily S&P Biotech Bull 3X Shares
0.29%
Inspire Small/Mid Cap ESG ETF
0.18%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Biotechnology ETF
0.1%
Pacer WealthShield ETF
0.08%
View more
Tema Oncology ETF
Proportion2.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.87%
State Street SPDR S&P Biotech ETF
Proportion0.47%
Simplify Health Care ETF
Proportion0.33%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.29%
Inspire Small/Mid Cap ESG ETF
Proportion0.18%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.11%
iShares Biotechnology ETF
Proportion0.1%
Pacer WealthShield ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Syndax Pharmaceuticals Inc?
The top five shareholders of Syndax Pharmaceuticals Inc are:
Kynam Capital Management LP holds 8.52M shares, accounting for 9.89% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.56M shares, accounting for 8.77% of the total shares.
The Vanguard Group, Inc. holds 5.01M shares, accounting for 5.82% of the total shares.
Goldman Sachs & Company, Inc. holds 5.20M shares, accounting for 6.03% of the total shares.
Point72 Asset Management, L.P. holds 2.13M shares, accounting for 2.47% of the total shares.
Kynam Capital Management LP holds 8.52M shares, accounting for 9.89% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.56M shares, accounting for 8.77% of the total shares.
The Vanguard Group, Inc. holds 5.01M shares, accounting for 5.82% of the total shares.
Goldman Sachs & Company, Inc. holds 5.20M shares, accounting for 6.03% of the total shares.
Point72 Asset Management, L.P. holds 2.13M shares, accounting for 2.47% of the total shares.
What are the top three shareholder types of Syndax Pharmaceuticals Inc?
The top three shareholder types of Syndax Pharmaceuticals Inc are:
Kynam Capital Management LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Kynam Capital Management LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of Syndax Pharmaceuticals Inc (SNDX)?
As of 2025Q3, 456 institutions hold shares of Syndax Pharmaceuticals Inc, with a combined market value of approximately 105.70M, accounting for 121.61% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.64%.
What is the biggest source of revenue for Syndax Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Syndax Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
